Topics

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Lymphoma, Non-Hodgkin,Arthritis, Rheumatoid,Leukemia, Lymphocytic, Chronic, B-Cell,Wegener Granulomatosis,Microscopic Polyangiitis, Date of authorisation: 15/06/2017, Revision:

06:02 EDT 3 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Lymphoma, Non-Hodgkin,Arthritis, Rheumatoid,Leukemia, Lymphocytic, Chronic, B-Cell,Wegener Granulomatosis,Microscopic Polyangiitis, Date of authorisation: 15/06/2017, Revision: 3, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Rixathon, rituximab, Lymphoma, Non-Hodgkin,Arthritis, Rheumatoid,Leukemia, Lymphocytic, Chronic, B-Cell,Wegener Granulomatosis,Microscopic Polyangiitis, Date of authorisation: 15/06/2017, Revision:

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Rixathon, rituximab, Lymphoma, Non-Hodgkin,Arthritis, Rheumatoid,Leukemia, Lymphocytic, Chronic, B-Cell,Wegener Granulomatosis,Microscopic Polyangiitis, Date of authorisation: 15/06/2017, Revision:"

Quick Search

Relevant Topic

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...